<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733042</url>
  </required_header>
  <id_info>
    <org_study_id>MEDI4736-NHL-001</org_study_id>
    <nct_id>NCT02733042</nct_id>
  </id_info>
  <brief_title>A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <acronym>FUSION NHL 001</acronym>
  <official_title>A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, multicenter, global study is designed to determine the recommended phase 2
      dose, safety, efficacy, and pharmacokinetics/pharmacodynamics of durvalumab in subjects with
      certain lymphoma subtypes or CLL. Globally, 265 subjects may be enrolled into 4 treatment
      arms, including durvalumab monotherapy; durvalumab in combination with lenalidomide±
      rituximab; ibrutinib; or rituximab ± bendamustine. The study will have 3 parts: dose finding,
      dose confirmation, and dose expansion. Subjects receiving monotherapy may receive combination
      therapy or involved-field radiation to a single nodal site at time of progressive disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2016</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)- Phase</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) - Phase 1</measure>
    <time_frame>Up to approximately 1 month</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Tolerated Dose (NTD)- Phase 1</measure>
    <time_frame>Up to approximately 1 month</time_frame>
    <description>A dose will be considered to be a non-tolerated dose (NTD) if ≥ 2 of 3 or 6 evaluable subjects in a dose level experience a Dose Limiting Toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)- Phase 1</measure>
    <time_frame>Up to approximately 1 month</time_frame>
    <description>Is defined as the highest dose level below the NTD with 0 of 3 or 1 of 6 (ie, &lt; 1/3 of subjects) evaluable subjects experiencing DLTs during the DLT evaluation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)- Phase 2</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Number of subjects with best disease response of complete response (CR) or partial response (PR) during durvalumab treatment based on the International Working Group (IWG) Response Criteria for Malignant Lymphoma (the Lugano Classification) (Cheson, 2014) or the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Response Criteria (Hallek 2008; 2012; 2013)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate- Phase 1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Number of subjects with best disease response of CR or PR during durvalumab treatment based on the IWG Response Criteria for Malignant Lymphoma (the Lugano Classification) or the IWCLL Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) - Phase 2</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate-Phase1/2</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Number of subjects with best disease response of CR or PR during study treatment based on the IWG Response Criteria for Malignant Lymphoma (the Lugano Classification) or the IWCLL Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)- Phase1/2</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Time from first response (CR/PR) to progressive disease (PD) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) - Phase 1/2</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Time from first study treatment dose to the first documented PD or death due to any cause, whichever occurs first time from first study treatment dose to the first documented PD or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Up to approximately 2 months</time_frame>
    <description>Area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Up to approximately 2 months</time_frame>
    <description>Time to maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2</measure>
    <time_frame>Up to approximately 2 months</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL/F</measure>
    <time_frame>Up to approximately 2 months</time_frame>
    <description>Apparent total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vz/F</measure>
    <time_frame>Up to approximately 2 months</time_frame>
    <description>volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Phase 1/2</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Individual soluble PDL-1 levels [pg/mL] in blood with durvalumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response(TTR)- Phase1/2</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Time from first IP dose to the first documented response (PR or CR)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Arm A: Durvalumab and Lenalidomide plus or minus Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm A will receive:
Durvalumab 1500 mg (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and
Lenalidomide (oral) at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 (inclusive) of:
Cycles 1 through 13 in indolent Non-Hodgkin lymphoma (NHL) (ie, FL or MZL) or
All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL
Rituximab 375 mg/m2 (IV) infusion Schedule 1 (dose levels 2 and -1B) on Days 2, 8, 15 and 22 of Cycle 1 and on Day 1 from Cycles 2 through 5.
Rituximab 375 mg/m2 (IV) infusion Schedule 2 (dose levels -2 and -3) on Day 2 of Cycle 1 and on Day 1 from Cycles 2 through 8.
One cycle is 28-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Durvalumab and Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm B will receive:
Durvalumab (IV) infusion on Day 1 of Cycles 1 through 13
Ibrutinib (oral) at assigned dose levels (280 mg, 420 mg, or 560 mg)continuous once daily until disease progression, unacceptable toxicity or discontinuation for any other reason One cycle is 28-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Durvalumab and Bendamustine plus or minus Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm C will receive:
Durvalumab 1500 mg (IV) infusion on Day 1 of Cycles 1 through 13
Bendamustine (IV) infusion at assigned dose levels (70 mg/m2 or 90 mg/m2) on Days 1 and 2 of Cycles 1 through 6
Rituximab 375 mg/m2 (IV) infusion on Day 2 Cycles 1 through 6 One cycle is 28-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Durvalumab Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm D will receive:
• Durvalumab (IV) infusion at a fixed dose of 1500 mg, on Day 1 of Cycles 1 through 13. One cycle is 28-day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <arm_group_label>Arm A: Durvalumab and Lenalidomide plus or minus Rituximab</arm_group_label>
    <arm_group_label>Arm B: Durvalumab and Ibrutinib</arm_group_label>
    <arm_group_label>Arm C: Durvalumab and Bendamustine plus or minus Rituximab</arm_group_label>
    <arm_group_label>Arm D: Durvalumab Monotherapy</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Arm A: Durvalumab and Lenalidomide plus or minus Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Arm A: Durvalumab and Lenalidomide plus or minus Rituximab</arm_group_label>
    <arm_group_label>Arm C: Durvalumab and Bendamustine plus or minus Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Arm B: Durvalumab and Ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <arm_group_label>Arm C: Durvalumab and Bendamustine plus or minus Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who has histologically confirmed and documented B-cell lymphoma (eg,
             follicular, diffuse large B-cell, mantle cell, small lymphocytic, or Hodgkin lymphoma)
             and chronic lymphocytic leukemia.

          2. Subject who has high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma.

          3. Subject who was previously treated with at least one prior systemic chemotherapy,
             immunotherapy, or chemoimmunotherapy.

          4. Subject who has the Eastern Cooperative Oncology Group performance status of 0, 1, or
             2.

          5. Subject who is willing and able to undergo biopsy.

          6. Subject who has documented active relapsed or refractory disease requiring therapeutic
             intervention.

          7. Subject with lymphoma who has measurable disease (≥ 2.0 cm in its longest dimension by
             computed tomography) or chronic lymphocytic leukemia in need of treatment.

          8. Subject who fulfills the laboratory requirements as per protocol

        Exclusion Criteria

          1. Subject who has central nervous system (CNS) or meningeal involvement by lymphoma.

          2. Subject who has any histopathologic finding consistent with myelodysplastic syndrome
             on bone marrow studies.

          3. Subject who received any prior monoclonal antibodies against PD-1 or PD-L1 and/or any
             prior:

               1. Arm A only: ImiDs (eg, lenalidomide, thalidomide);

               2. Arm B only: ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitor;

               3. Arms C only: bendamustine

          4. Subject who has active auto-immune disease.

          5. Subject who has history of organ transplant or allogeneic hematopoietic stem cell
             transplantation.

          6. Subject who is seropositive for or active viral infection with hepatitis B virus (HBV)
             (hepatitis B surface antigen [HBsAg] positive and/or detectable viral DNA)

          7. Subject who has known seropositivity for or active infection for human
             immunodeficiency virus (HIV) or hepatitis C virus (HCV).

          8. Subject who has history of primary immunodeficiency or tuberculosis.

          9. Subject who other invasive malignancy within 2 years (5 years for Arm A) except for
             noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous
             carcinoma of the skin, ductal carcinoma in situ of the breast, or incidental
             histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes,
             metastasis] clinical staging system) that has/have been surgically cured.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron S Czuczman</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Oncology Hematology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Cancer Center University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Medical Oncology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Avicennes</name>
      <address>
        <city>Bobigny Cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud Hematologie</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKG Universitatsklinikum Gottingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum des Saarlandes</name>
      <address>
        <city>Homburg-Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Koln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili Di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEO- Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Ca Granda - Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale</name>
      <address>
        <city>Napoli, Campania</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Humanitas Clinical Institute</name>
      <address>
        <city>Rozzano (milano)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara City, Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Academic Medical Center, Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>Ng5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospotal - Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>0X3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Anti-PD-L1 Antibody</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Immune Checkpoint</keyword>
  <keyword>Lymphatic Disease</keyword>
  <keyword>B-Cell Malignancies</keyword>
  <keyword>Abscopal Effect</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Non Hodgkin,</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Leukemia, Lymphocytic, Chronic, B-Cell,</keyword>
  <keyword>Lymphoma, Follicular</keyword>
  <keyword>Lymphoma, Diffuse Large B-Cell</keyword>
  <keyword>Lymphoma, Mantle Cell</keyword>
  <keyword>Lymphoma, Small Lymphocytic</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

